Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Inclusion Criteria:

1. Chronic hepatitis B virus infection with documentation at least 6 months prior to screening
2. Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently for ≥12 months prior to dosing Day 1
3. HBV DNA
4. HBsAg between 100 and 5,000 IU/mL at Screening
5. Subjects must be HBeAg-negative at Screening
6. Fibroscan® result of ≤8.5 kPa within 6 months prior to dosing Day 1
7. Medically stable based on physical examination, medical history, vital signs, laboratory values, and 12-lead Electrocardiogram (ECG) at screening

Exclusion Criteria:

1. Evidence of co-infection with hepatitis A, C, D or E virus or human immunodeficiency virus (HIV) at screening
2. History of any clinically significant medical condition associated with chronic liver disease, cirrhosis, evidence of decompensated liver disease, or findings suggestive of hepatocellular carcinoma (HCC) at any time
3. Contraindications to the use of Peg-IFNα-2a or incapable of self-administration or assisted administration of Peg-IFNα-2a
4. Previous treatment with an experimental HBV-directed RNA-interference or antisense oligonucleotide product.